GeneDx Holdings Corp. Class A Common Stock (WGS) Stock Price
WGSStock
$84.81−33.07%52W
Market Cap$2.53B
P/E—
PEG Ratio—
Div yield—
Beta1.99
WGS Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-4.95%
Price vs S&P 500 (4W)25.68%
VGM Score46.41
WGS Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.19 | $0.01 | +105.33%(+$0.20) | |
| Q1 2026 | -$0.02 | -$0.28 | -1407.81%(-$0.26) | |
| Q4 2025 | $0.12 | $0.14 | +16.67%(+$0.02) | |
| Q3 2025 | $0.42 | $0.49 | +15.88%(+$0.07) | |
| Q2 2025 | $0.11 | $0.50 | +371.70%(+$0.39) |
WGS Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.23
4.23
4.23
4.23
Industry Peers — Health Services(21)
| Symbol | Value Score | Growth Score | Momentum Score | P/E Ratio (Annual) | Revenue Growth TTM (YoY) | Operating Margin (TTM) | ROE (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
WGSGeneDx Holdings Corp. Class A Common Stock | F | B | C | — | 25.4% | -21.8% | -38.7% | $84.81 |
| LFSTLifeStance Health Group, Inc. Common Stock | D | B | A | 483.2x | -12.8% | 3.0% | 1.6% | $12.36 |
| PRVAPrivia Health Group, Inc. Common Stock | C | B | D | 121.3x | 24.1% | 1.9% | 3.8% | $20.49 |
| PIIIP3 Health Partners Inc. Common Stock | A | C | C | — | 2.8% | -9.9% | 10.3% | $9.06 |
| OMDAOmada Health, Inc. Common Stock | F | A | B | — | — | -3.7% | -2.8% | $24.55 |
| INNVInnovAge Holding Corp. Common Stock | D | C | B | — | 14.1% | -1.0% | -4.8% | $10.80 |
| PNTGThe Pennant Group, Inc. Common Stock | D | B | C | 45.9x | 37.9% | 5.7% | 9.5% | $36.76 |
| USPHUS Physical Therapy Inc | C | D | C | 30.9x | 13.7% | 10.0% | 7.1% | $77.74 |
| TALKTalkspace, Inc. Common Stock | F | B | B | 111.7x | 22.6% | -1.2% | 1.0% | $5.25 |
| SRTAStrata Critical Medical, Inc. Class A Common Stock | C | B | C | 12.8x | 18.8% | -8.0% | 14.3% | $5.66 |
| ALPSALPS Group Inc Ordinary Share | — | — | D | — | — | — | — | $0.39 |
About GeneDx Holdings Corp. Class A Common Stock
GeneDx Holdings develops exome and genome sequencing technologies for diagnosing rare and ultra-rare pediatric genetic disorders. The company addresses a growing market opportunity as genetic testing becomes the standard diagnostic approach, enabling earlier diagnoses and improved patient outcomes. With a core business in pediatric and rare disease diagnostics, GeneDx is expanding into data and information services as precision medicine adoption accelerates.